^
    20h
    FRUQUITAS: Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma (clinicaltrials.gov)
    P3, N=324, Recruiting, Federation Francophone de Cancerologie Digestive
    Trial initiation date
    |
    CLDN18 (Claudin 18)
    |
    Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    1d
    Heparanase blockade sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy and unleashes antitumor immunity. (PubMed, Biomed Pharmacother)
    Importantly, triple therapy with PI-88, gemcitabine, and Abraxane significantly suppressed tumor growth and prolonged survival relative to all mono- and doublet regimens. Immune profiling revealed that this combination reduced PSC activation, contracted M2 macrophage and regulatory T cell populations, and expanded M1 macrophages, CD8⁺ T cells, and NK cells. In conclusion, these data underscore HPSE as a key driver of fibrosis and chemoresistance in PDAC and support HPSE inhibition as a promising strategy to enhance therapeutic efficacy.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    gemcitabine • albumin-bound paclitaxel • muparfostat (PI-88)
    3d
    Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment (clinicaltrials.gov)
    P2, N=80, Recruiting, Advenchen Pharmaceuticals, LLC. | N=36 --> 80 | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2027 | Active, not recruiting --> Recruiting
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    3d
    TiNivo-2: Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma (clinicaltrials.gov)
    P3, N=343, Completed, AVEO Pharmaceuticals, Inc. | Active, not recruiting --> Completed | Trial primary completion date: Sep 2025 --> Jan 2026
    Trial completion • Trial primary completion date • Checkpoint inhibition
    |
    Opdivo (nivolumab) • Fotivda (tivozanib)
    5d
    Identification of RPL4 as a biomarker associated with disulfidptosis and arachidonic acid metabolism in breast cancer. (PubMed, Discov Oncol)
    This machine learning-driven disulfidptosis-related and arachidonic acid metabolism-related model provides clinically actionable prognostic stratification, outperforming conventional gene signatures in precision oncology applications. RPL4 is a potential candidate biomarker associated with disulfidptosis and AAM-related pathways in breast cancer, and its potential as a therapeutic target requires further experimental validation.
    Journal • IO biomarker
    |
    PRDX1 (Peroxiredoxin 1) • CLDN7 (Claudin 7) • PYCARD (PYD And CARD Domain Containing)
    |
    axitinib
    6d
    Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling. (PubMed, NPJ Precis Oncol)
    In this study, we evaluated a novel liquid biopsy platform based on circulating cell-free DNA active chromatin (cfDNAac) profiling to identify baseline biomarkers associated with clinical benefit rate (CBR) in 30 LMS patients treated with durvalumab plus olaparib or cediranib. In this analysis, cfDNAac profiling represents a promising non-invasive strategy to predict clinical benefit from CPI-based therapy in LMS. Prospective validation in independent cohorts is warranted to clarify its clinical utility.
    Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
    6d
    VEGFR-2 blocker induces pulmonary vascular disease in rats with CRISPR-edited human non-deficient G6PD polymorphism: role of 3D genomic modifications and DNA methylation. (PubMed, Br J Pharmacol)
    This suggests that our findings reflect a heretofore unknown connection between G6PD polymorphisms and the 3D genomic organization that controls VEGFR blocker-induced expression of DNA/histone demethylases. Potential effects include up-regulation of genes encoding proteins, which evoke cell migration and inflammation within the lungs and contribute to the pathogenesis of PVD.
    Preclinical • Journal
    |
    KDR (Kinase insert domain receptor) • IL1B (Interleukin 1, beta)
    |
    semaxanib (SU5416)
    9d
    Fatty acid β-oxidation-associated prognostic model in gastric cancer and functional validation of IL-6 as a potential therapeutic target. (PubMed, Sci Rep)
    Immune infiltration analysis and drug sensitivity testing (e.g. AG-014699, Axitinib, BX-795, and Cisplatin) were also conducted. IL-6 emerged as a core gene with significant expression difference across cellular and tissue levels. FAO plays a critical role in the prognosis of GC, and IL-6 may serve as a key biomarker for diagnosis and therapeutic strategies.
    Journal • PARP Biomarker
    |
    IL6 (Interleukin 6) • CD36 (thrombospondin receptor) • G0S2 (G0/G1 Switch 2) • GABARAPL1 (GABA Type A Receptor Associated Protein Like 1)
    |
    cisplatin • Rubraca (rucaparib) • axitinib
    10d
    NCI-2015-01097: A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=122, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 expression • ALK mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    11d
    Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=155, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2026 --> Mar 2027
    Trial completion date
    |
    BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    11d
    Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2026 --> Mar 2027
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    12d
    SWOG S0905: Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma (clinicaltrials.gov)
    P1/2, N=117, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    cisplatin • pemetrexed • Recentin (cediranib)